Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression

Anticancer Research

Volumn 14, Issue 6 B, 1994, Pages 2773-2778

  Jacquemier, J ^a   Penault Llorca, F ^a   Viens, P ^a   Houvenaeghel, G ^a   Hassoun, J ^a   Torrente, M ^a   Adelaide, J ^a   Birnbaum, D ^a  

^a Institut Paeli Calmettes ^*  (France)

Author keywords

Breast cancer; Chemotherapy; erbB2; Immunohistochemistry; Oncogene; p53

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; MITOXANTRONE; ONCOPROTEIN; PROTEIN P53; TUMOR ANTIGEN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMPARATIVE STUDY; FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGE; MITOXANTRONE; OVARIECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN P53; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0028652334     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)